Single-Blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell-Derived) in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 2004/2005.

Next Previous
Trial Profile

Single-Blind Randomized Controlled Phase II/III Study to Investigate the Immunogenicity and Safety After a Single Vaccination With Three Different Lots of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell-Derived) in Comparison to a Licensed Egg Derived Influenza Vaccine for Season 2004/2005.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Baxter BioScience; Baxter Healthcare Corporation; Baxter Vaccines

    • Most Recent Events

    • 06 Jul 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2004-001374-34).
    • 27 Oct 2006 Status change
    • 08 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top